The company develops innovative new treatments for cancer and brain diseases that are associated with aberrant activation of the MAPKinase/ERK signaling pathway. They avoid the deleterious global inhibition of the entire cascade and allow modulating specifically cell functions involved in pathological processes.
Pepsignal® easily passes across the cell membrane and acts directly in the nucleus, where it interferes with MAPKinase/ERK binding to specific downstream substrates.
